News

GoHealth's Upcoming Earnings: What Investors Should Know

GoHealth's Upcoming Earnings: What Investors Should Know

GoHealth's Earnings Announcement Overview

GoHealth (NASDAQ: GOCO) is set to release its quarterly earnings report soon. Investors are likely keenly awaiting updates, as they provide crucial information on the company's financial health and future prospects.

Expected Earnings Per Share

Analysts currently predict that GoHealth will report an earnings per share (EPS) of $-2.02 for this quarter, a figure that highlights the challenges the company faces.

Past Earnings Performance Analysis

In the previous quarter, GoHealth fell short of EPS expectations by $2.50, which triggered a significant 2.44% decline in the stock price the following day. The anticipated figures provide a juxtaposition against GoHealth’s past performance.

Overview of Previous Earnings Reports

To better understand its trajectory, let’s revisit GoHealth’s recent earnings record:

Quarterly EPS Estimates vs. Actuals:

- **Q2 2025**: Estimate $-2.60, Actual $-5.10 (Price Change: -2.0%)

- **Q1 2025**: Estimate $-0.26, Actual $-0.52 (Price Change: -8.0%)

- **Q4 2024**: Estimate $1.16, Actual $1.56 (Price Change: -8.0%)

- **Q3 2024**: Estimate $-3.19, Actual $-4.85 (Price Change: +1.0%)

Market Performance of GoHealth's Stock

As of the latest update, GoHealth shares were trading at approximately $3.42, marking a staggering decline of over 72.54% over the past year. This dip raises concerns for long-term shareholders who are understandably apprehensive leading up to the earnings release.

Insights from Analysts

For anyone involved in GoHealth or considering an investment, it's vital to stay tuned to market sentiments and expectations. The general consensus among analysts currently rates GoHealth as Neutral, based on one analyst rating. The average price target over the next year stands at $12.0, suggesting a potential upside of nearly 250.88% if targets are met.

Comparative Analysis with Industry Peers

Understanding how GoHealth stacks up against its competitors is crucial for assessing market positions. When looking at key industry players, GoHealth's performance metrics and analyst ratings reveal significant insights into relative market dynamics.

Snapshot of Peer Analysis

This section will encapsulate essential metrics for GoHealth in comparison with its peers:

- **Consensus Rating**: Neutral

- **Revenue Growth**: -11.17%

- **Gross Profit**: $61.64M

- **Return on Equity**: -25.50%

Understanding GoHealth's Market Position

GoHealth Inc is a digital health marketplace that primarily focuses on health insurance, specifically Medicare plans, including Medicare Advantage, Supplement, and prescription drug plans. The company's technology aims to simplify the healthcare decision-making process for consumers.

Financial Performance Breakdown

Let’s delve deeper into GoHealth's financial landscape:

Market Capitalization: GoHealth's market cap suggests a smaller scale than many of its competitors, influenced by variable factors affecting growth expectations and business operations.

Revenue Decline: In the last quarter, the company registered a revenue decline of -11.17%, indicating tough market conditions forcing adjustments to business strategies.

Net Margin: Currently, GoHealth's net margin shows a trend below industry averages, revealing probable difficulties in managing costs effectively.

Return on Equity (ROE): The company's ROE remains significantly lower than expected, which may raise concerns for current and prospective shareholders about their returns.

Asset Utilization: GoHealth's return on assets (ROA) also lags behind industry competitors, indicating possible inefficiencies in asset management.

Debt Management: GoHealth's debt-to-equity ratio exceeds industry averages at 3.11, suggesting heightened levels of debt that could impact financial stability.

Frequently Asked Questions

What is GoHealth's anticipated earnings per share?

GoHealth is expected to report an EPS of $-2.02.

How has GoHealth performed in past quarters?

GoHealth missed EPS expectations last quarter by $2.50, leading to a stock price drop.

How does GoHealth's stock perform compared to its peers?

GoHealth has experienced a dramatic decline of 72.54% over the past year, making it underperform compared to industry standards.

What are analyst expectations for GoHealth's stock price?

The average price target stands at $12.0, suggesting a potential upside of 250.88%.

What is GoHealth's approach in the market?

GoHealth aims to assist consumers in health plan selection through technology focused on Medicare solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 100

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Surprising Week on Wall Street: Chips Drive Gains

Updated Category News Views 141

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 141

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 83

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 99

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 155

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Gemmy's Holiday Lights: Bright Ideas for 2026

Updated Category News Views 149

Deep in the heart of Dallas, Gemmy Industries is out to sprinkle a bit of magic over the holiday season for 2026. This ain't your grandma's string lights we're talkin' about here. We're diving headfirst into a new world of seasonal decor with tech-driven lights that look like they came straight outta a winter wonderland. And hey, if Walmart's set to host this lineup, you...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 177

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading

Top 5 Most Recently Viewed Articles

NexPoint Capital Launches Tender Offer for Shareholders

Updated Category News Views 217

NexPoint Capital Begins Tender Offer for Its Common Stock NexPoint Capital, Inc. (the "Company"), a publicly registered business development company expertly managed by NexPoint Advisors, L.P., is set to kick off a voluntary tender offer aimed at going after up to 2.5% of its outstanding common shares. This offer is designed to provide shareholders an opportunity to sell...

Continue Reading
Experience the Winter Wheat Wonderland Pop-Up by Maker's Mark

Updated Category News Views 223

Immerse Yourself in Maker's Mark's Winter Wheat Wonderland Get ready to experience something truly unique this holiday season as Maker's Mark unveils its enchanting pop-up event, the Winter Wheat Wonderland. This special event will take the vibrant spirit of Kentucky bourbon to the heart of New York City, creating a magical atmosphere for all attendees. Details of the...

Continue Reading
Innovative Muscle Composition Study Enhances Liver Transplant Care

Updated Category News Views 202

Assessment of Muscle Composition in Liver Transplant Candidates In a groundbreaking study, the utilization of AMRA Profiler 4, an advanced body-composition analysis device, was analyzed for its effectiveness in evaluating muscle composition among liver transplant candidates suffering from end-stage liver disease (ESLD). This study aims to shed light on critical health...

Continue Reading
Hansa Biopharma's Major Milestones Anticipated in 2025

Updated Category News Views 688

Hansa Biopharma's Participation in Healthcare Conferences Hansa Biopharma AB, a pioneering biopharmaceutical company, is set to make a significant presence at the 2025 J.P. Morgan Healthcare Conference. The company is renowned for its innovative approaches in addressing rare immunological disorders and has been actively engaged in developing novel therapies. This...

Continue Reading
AI for Customer Service: The Next Big Market Leap Ahead

Updated Category News Views 137

AI for Customer Service Market Growth Overview The AI for customer service market is on a remarkable trajectory, set to expand significantly over the next few years. Current projections indicate that the market size will grow from USD 12.06 billion in the near term to an impressive USD 47.82 billion by the end of the decade, achieving a compound annual growth rate (CAGR)...

Continue Reading